标题
Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
作者
关键词
-
出版物
ARCHIVES OF VIROLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-01-25
DOI
10.1007/s00705-021-04956-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings
- (2020) Pascale M. Abena et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know
- (2020) Jinoos Yazdany et al. ANNALS OF INTERNAL MEDICINE
- Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review
- (2020) Adrian V. Hernandez et al. ANNALS OF INTERNAL MEDICINE
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
- (2020) Yin‐Xiao Du et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV
- (2020) Mingxuan Xie et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective
- (2020) Abdo A. Elfiky JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
- (2020) Qingxian Cai et al. Engineering
- Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
- (2020) Shiv Kumar Sarin et al. Hepatology International
- Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials
- (2020) Morteza Arab-Zozani et al. BMJ Open
- RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery
- (2020) Wei Zhu et al. SLAS Discovery
- Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study
- (2020) Thomas Marjot et al. JOURNAL OF HEPATOLOGY
- Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country
- (2020) Sherief Abd-Elsalam et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- SARS-CoV-2: The Path of Prevention and Control
- (2020) Amal A. Mohamed et al. Infectious Disorders - Drug Targets
- Chloroquine as Chemoprophylaxis for COVID-19: Will This Work
- (2020) Sherief Abd-Elsalam et al. Infectious Disorders - Drug Targets
- The mechanism of resistance to favipiravir in influenza
- (2018) Daniel H. Goldhill et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MERS, SARS and other coronaviruses as causes of pneumonia
- (2017) Yudong Yin et al. RESPIROLOGY
- Ebola virus dynamics in mice treated with favipiravir
- (2015) Vincent Madelain et al. ANTIVIRAL RESEARCH
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
- (2014) Lisa Oestereich et al. ANTIVIRAL RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started